Results 211 to 220 of about 5,124 (246)
Some of the next articles are maybe not open access.
Hospital Pharmacy, 2016
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +3 more sources
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +3 more sources
pharma-kritik, 2017
Dieses Medikament wirkt der Antikoagulation durch den direkten Thrombinhemmer Dabigatran entgegen. Sein praktischer Nutzen ist aber bisher nicht genügend dokumentiert. Da auch sein Nebenwirkungspotential noch nicht geklärt ist, kann die Verwendung dieses sehr teuren Mittels wohl am ehesten noch im Rahmen weiterer Studien verantwortet werden.
+4 more sources
Dieses Medikament wirkt der Antikoagulation durch den direkten Thrombinhemmer Dabigatran entgegen. Sein praktischer Nutzen ist aber bisher nicht genügend dokumentiert. Da auch sein Nebenwirkungspotential noch nicht geklärt ist, kann die Verwendung dieses sehr teuren Mittels wohl am ehesten noch im Rahmen weiterer Studien verantwortet werden.
+4 more sources
Russian neurological Journal, 2023
Dabigatran etexilate (DE) is a direct thrombin inhibitor that has been shown to be eff ective and safe in preventing thrombotic events in a number of studies.
G. Ramazanov +5 more
semanticscholar +1 more source
Dabigatran etexilate (DE) is a direct thrombin inhibitor that has been shown to be eff ective and safe in preventing thrombotic events in a number of studies.
G. Ramazanov +5 more
semanticscholar +1 more source
Laboratory-guided repeat dosing of idarucizumab for dabigatran reversal
Clinical toxicology, 2023was limited due to poor contrast opacification of the distal circulation. Multiple therapies, including topical nitroglycerine, subcutaneous phentolamine, and a nitroprusside drip, were administered with no improvement.
Heather Jones +2 more
semanticscholar +1 more source
Idarucizumab (Praxbind) Formulary Review
Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2016Idarucizumab (Praxbind), a humanized monoclonal antibody fragment was granted accelerated approval from the Food and Drug Administration in October 2015 as the first agent to reverse the effects of a novel oral anticoagulant. The drug is indicated for dabigatran reversal in patients requiring emergency surgery/urgent procedures or with life-threatening
Jessica, Buchheit +2 more
openaire +2 more sources
Circulation, 2015
Four non–vitamin K antagonist oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, are currently licensed as alternatives to heparins and vitamin K antagonists for the prevention and treatment of venous thromboembolism and for the prevention of stroke in
John W, Eikelboom +3 more
openaire +2 more sources
Four non–vitamin K antagonist oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, are currently licensed as alternatives to heparins and vitamin K antagonists for the prevention and treatment of venous thromboembolism and for the prevention of stroke in
John W, Eikelboom +3 more
openaire +2 more sources